| Literature DB >> 24209891 |
Ranjith Munigunti, Symon Gathiaka, Orlando Acevedo, Rajnish Sahu, Babu Tekwani, Angela I Calderón1.
Abstract
BACKGROUND: The compounds 1,4-napthoquinone (1,4-NQ), bis-(2,4-dinitrophenyl)sulfide (2,4-DNPS), 4-nitrobenzothiadiazole (4-NBT), 3-dimethylaminopropiophenone (3-DAP) and menadione (MD) were tested for antimalarial activity against both chloroquine (CQ)-sensitive (D6) and chloroquine (CQ)-resistant (W2) strains of Plasmodium falciparum through an in vitro assay and also for analysis of non-covalent interactions with P. falciparum thioredoxin reductase (PfTrxR) through in silico docking studies.Entities:
Year: 2013 PMID: 24209891 PMCID: PMC3828397 DOI: 10.1186/1752-153X-7-175
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Figure 1The five TrxR inhibitors.
TrxR inhibitory and antiplasmodial activities of tested compounds
| 1,4-NQ | 0.75 | 8.9 ± 2.3 | 4.6 | 16.7 ± 3.7 | 2.4 | 38.5 ± 0.76 |
| 2,4-DNPS | 0.5 | 91.2 ± 11.3 | 0.8 | 72.3 ± 11.3 | 1.0 | 79 ± 3.51 |
| 4-NBT | 2 | 8.3 ± 2.1 | 10 | 9.8 ± 1.9 | 8 | 80 ± 1.15 |
| 3-DAP | 15.4 | >100 | >1 | >100 | >1 | >100 |
| MD | 1.6 | 18.5 ± 1.9 | 3.8 | 28.3 ± 5.6 | 2.5 | 70.5 ± 3.69 |
| CQ | 0.055 ± 0.006 | 0.440 ± 0.045 | NC |
*IC50 values, preparation of PfTrxR and optimal experimental conditions for the PfTrxR functional assay were reported in Andricopulo et al., 2006 [12]; Charvet et al., 2003 [13]; Munigunti et al., 2012 [14].
**Values are mean ± S.D. of triplicate observations; SI: Selectivity index. NC: no cytotoxicity up to concentration much higher than the concentration responsible for its antiplasmodial activity.
Predicted physico-chemical properties of the compounds
| 1,4 NQ | 0.486 | −0.764 | 57.199 | 954 | 470 |
| 2,4 DNPS | 1.406 | −3.444 | 177.135 | 5 | 2 |
| 4-NBT | 0.746 | −1.414 | 75.626 | 382 | 385 |
| 3-DAP | 1.249 | −0.313 | 32.353 | 819 | 441 |
| 3-DAP-enol | 1.800 | −1.170 | 25.296 | 842 | 454 |
| MD | 0.880 | −1.312 | 55.456 | 1225 | 616 |
| CQ | 4.276 | −3.585 | 24 | 1364 | 1862 |
| Range 95% of drugs | (−2.0 / 6.5) | (−6.5 / 0.5) | (7.0 / 330.0) | (<25 poor, >500 great) | (<25 poor, >500 great) |
Figure 2Formation of reactive oxygen species (ROS), as indicated by increase in fluorescence. DCFDA loaded human erythrocytes by five PfTrxR inhibitors.
Comparison between computed binding affinities at the dimer interface in TrxR and experimental IC values
| 2,4-DNPS | −8.4 | 0.5 |
| MD | −7.9 | 1.6 |
| 4-NBT | −6.0 | 2 |
Figure 3The predicted binding poses for the inhibitors showing the main interactions with the dimer interface residues.PfTrxR/MD, PfTrxR/4-NBT, and PfTrxR/2, 4-DNPS complexes.
Comparison between computed binding affinities at the dimer interface and experimental IC values in TrxR and TrxR
| 2,4-DNPS | Exptl. IC50(μM) | 0.5 | 4 |
| Calc. binding affinity (kcal/mol) | −8.4 | −8.1 | |
| 4-NBT | Exptl. IC50(μM) | 2 | 50 |
| Calc. binding affinity (kcal/mol) | −6.0 | −5.7 |
Figure 4The docking pose differences of 2,4-DNPS and 4-NBT between the - (brown) and -TrxR (blue). The docked structures point to the difference in conformation between Try101 (pfTrxR) and Glu72 (hTrxR) which is proposed to have significant contribution to the observed experimental selectivity.
Figure 5The predicted binding mode of 2,4-DNPS in the TrxR (beige) and TrxR (blue) showing the position of the residues Try101 ( TrxR) and Glu72 ( TrxR).